Compare NTCT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTCT | HCM |
|---|---|---|
| Founded | 1984 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 1999 | 2015 |
| Metric | NTCT | HCM |
|---|---|---|
| Price | $33.16 | $13.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $42.50 | $21.14 |
| AVG Volume (30 Days) | ★ 435.5K | 37.1K |
| Earning Date | 11-05-2026 | 07-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.39 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $891,820,000.00 | N/A |
| Revenue This Year | $4.76 | $14.11 |
| Revenue Next Year | $2.48 | $11.97 |
| P/E Ratio | $42.59 | ★ $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.29 | $9.77 |
| 52 Week High | $45.28 | $16.33 |
| Indicator | NTCT | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 37.65 | 40.65 |
| Support Level | $31.44 | $13.00 |
| Resistance Level | $34.14 | $14.74 |
| Average True Range (ATR) | 1.43 | 0.38 |
| MACD | -0.13 | -0.10 |
| Stochastic Oscillator | 26.99 | 17.90 |
NetScout Systems Inc is engaged in providing enterprise network observability, carrier service assurance, cybersecurity, and Distributed Denial-of-Service (DDoS), protection solutions. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.